ENABLING A NEW STANDARD OF CARE TO FIGHT STROKE AND SAVE LIVES

Medical need

Worldwide an estimated 15 million people suffer from Stroke every year. This brain disease often leads to death or severe disabilities.

Currently, the best remedy for stroke patients is often surgery with the help of image-guided techniques (X-rays) to penetrate the brain and deliver a treatment. However, this procedure can be very challenging as the navigation takes place in a dense network of tiny brain arteries.

This complexity causes surgeons to lose much time before they can deliver a life-saving treatment. Artiria was founded to address this strong medical need.

About Artiria

ARTIRIA empowers catheters and guidewires. We develop cutting edge technologies to bring micromotion deep in the brain arteries, enabling a seamless navigation and stroke treatment.

ARTIRIA comprises a passionate team willing to bring a new standard of care to stroke surgeons for the benefit of their patients.

Follow Artiria’s latest NEWS:

The Team

Artiria Medical was founded in 2019 at the Lausanne Technical University (EPFL) by Guillaume Petit- Pierre and Marc Boers. Based in Switzerland, Artiria’s team is composed of entrepreneurial professionals with mechanical, medical and industrial Medtech experience.

Guillaume Petit-Pierre

CEO & Founder
PhD -EPFL bioengineering

Marc Boers

COO & Founder
MSc – EPFL microtechnology

Elodie Dahan

R&D Manager
PhD - EPFL microtechnology

Join us

Open positions are listed below
We look forward to receiving your application!

Qualitiy Manager

We are looking for a dynamic & motivated Quality Manager to join us!

Our vision

ARTIRIA’s mission is to help to reduce the mortality and morbidity after a stroke. With our straight forward, minimally invasive approach, we want to solve a strong unmet medical need. Exploiting ongoing innovation with the high standards of Swiss quality, Artiria aims to lead in the development of the next-generation products for endovascular surgeons.

Awards & supporters

At Artiria Medical, we are highly grateful for all the support received from our partners.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 886909.